China-based innovation, CDMOs and parallel approvals driving huge growth in manufacturing at CPhI China

cphi-china

Significant increase in exhibitors driven by bio growth at bioLIVE and separate nutraceuticals event

CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organised by UBM EMEA, CCCMHPIE, and UBM Sinoexpo will take place at the Shanghai New International Expo Center (SNIEC) from 18th to 20th June 2019. The event will be co-located with ICSE, InnoPack, bioLIVE, NEX, Labworld, FDF, and EP and Clean Tech. Seen as the bellwether of pharmaceutical trends across the country, CPhI & P-MEC China’s agenda is packed with content from over 100 onsite conferences and activities as well as more than 50 seminars, with speakers from China and abroad.

One of the key trends to emerge this year is the rise in the number of innovative China-based biotechs – coupled with the easing of regulatory pathways and an emerging CDMO sector – is fueling a significant growth in manufacturing across China. In view of this, experts at the event will assess the Marketing Authorization Holder (MAH) Pilot Program, as well as recent reforms of China’s regulatory landscape and the opportunities for international pharma.

With the Chinese pharma growing at a ferocious pace, CPhI & P-MEC China is expected to welcome 70,000 attendees in its 19th edition – an year-on-year increase of 55 per cent – which is further indicative of the buoyancy of the Chinese market. The event is also expected to see a six per cent increase in exhibitors, with more than 3,200 from over 120 countries in attendance.

“China is issuing new guidelines at a feverish pace and will be harmonised with ICH very quickly. The result is that over the next two to three years, poorer quality manufacturers will drop out of the market and China’s manufacturers will look to compete in international as well as domestic markets ,” said CPhI Annual Report Expert, Bikash Chatterjee, on outlook of 2019.

Wider market data also supports this ongoing boom, with China’s pharmaceutical market projected to grow strongly from $115.2 billion in 2016 to $159.4 billion by 2021 and $234.2 billion by 2026. This represents a 10-year compound annual growth rate of 8.8 per cent in local currency terms and 7.3 per cent in US dollar terms. Similarly, bioprocessing in China has been on a trajectory of rapid growth, with a 39 per cent growth in facilities, and total capacity is growing ≥eight per cent annually, with biosimilars offering the largest growth potential.

At the 2019 edition, for the first time, CPhI & P-MEC China 2019 will launch bioLIVE – their new bioprocessing and manufacturing exhibition – which has evolved from the previous BioPh China and will run adjacent. This exposition is in response to the large molecule trend within the industry, and arrives at a particularly prominent moment. Within the last year, there has been a proliferation of biosimilars and double-digit approvals of biologics – as well as a host of investments taking place in contract services.

Marie Lagrenee, Brand Manager at CPhI & P-MEC China, commented, “The growth of the Chinese pharma economy has been exponential in recent years, with regulatory reforms spearheading the increased interest in the region from both domestic and international companies. With a bourgeoning CDMO sector and recent harmonisation by ICH, it’s pivotal that events such as CPhI & P-MEC China provide a platform to drive growth, exchange new ideas and expedite new deals to help nurture this budding market.”

The third edition of China Pharma Week will take place alongside CPhI & P-MEC China from 17 – 21 June, 2019 focusing on leadership, business, networking, innovation, recognition and knowledge. Activities will include plant visits, a networking dinner, women in leadership forum, summits and the innovation gallery tours, giving a deeper work floor insight and dedicated industry conferences on different sectors.